4//SEC Filing
Calvin Sandra 4
Accession 0001882909-25-000004
CIK 0001438533other
Filed
Nov 5, 7:00 PM ET
Accepted
Nov 6, 4:05 PM ET
Size
23.9 KB
Accession
0001882909-25-000004
Insider Transaction Report
Form 4
Calvin Sandra
SVP, CHIEF ACCOUNTING OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-11-04$25.25/sh+10,000$252,500→ 64,410 total - Exercise/Conversion
Common Stock
2025-11-04$27.50/sh+15,000$412,500→ 96,910 total - Exercise/Conversion
Common Stock
2025-11-04$8.93/sh+6,250$55,813→ 115,660 total - Exercise/Conversion
Employee stock option (right to buy)
2025-11-04−10,000→ 0 totalExercise: $25.25Exp: 2028-05-10→ Common Stock (10,000 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-11-04−15,000→ 2,500 totalExercise: $27.50Exp: 2032-01-31→ Common Stock (15,000 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-11-04−12,500→ 7,500 totalExercise: $22.40Exp: 2033-01-31→ Common Stock (12,500 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-11-04−6,250→ 18,750 totalExercise: $8.93Exp: 2034-01-31→ Common Stock (6,250 underlying) - Exercise/Conversion
Common Stock
2025-11-04$22.40/sh+12,500$280,000→ 109,410 total - Sale
Common Stock
2025-11-04$36.00/sh−67,115$2,416,140→ 48,545 total - Exercise/Conversion
Employee stock option (right to buy)
2025-11-04−17,500→ 0 totalExercise: $26.88Exp: 2031-01-21→ Common Stock (17,500 underlying) - Exercise/Conversion
Common Stock
2025-11-04$26.88/sh+17,500$470,400→ 81,910 total
Footnotes (5)
- [F1]This sale was made pursuant to a written plan adopted on June 10, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- [F2]The stock option is fully vested and exercisable.
- [F3]One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F4]One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F5]One-fourth of the shares subject to the stock option vested and became exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001882909
Filing Metadata
- Form type
- 4
- Filed
- Nov 5, 7:00 PM ET
- Accepted
- Nov 6, 4:05 PM ET
- Size
- 23.9 KB